Neuro-oncology Certification Examination Committee Contributors
Jeffrey C. Allen, MD, FAAN, NYU Langone Medical Center
Disclosures: Receives grant support from Department of Defense for institutional leadership of a grant for the NF Clinical Trials Consortium.
Joy Ellen Burke, MD, University of Rochester
Disclosures: Receives compensation for consulting with Allergan regarding a migraine product.
Howard Colman, MD, Chair, University of Utah Huntsman Cancer Institute
Disclosures: Serves on Advisory Board/Consultant for Best Doctors, Karyopharm Therapeutics, Private Health, Orbus, Bayer, and Forma Therapeutics. Receives research Funding (Site PI/Institutional Contract) from Newlink Genetics, Plexxikon, Kadmon, Orbus, Merck, DNATrix, Abbvie, Beigene, Forma Therapeutics, GCAR, and Array BioPharma. Receives research funding and research-related salary support from National Institutes of Health/National Cancer Institute, Alliance NCORP Research Base, NIH/NINDS, Huntsman Cancer Institute, and Jon M. Huntsman Presidential Endowed Chair.
Kurt A. Jaeckle, MD, FAAN, Atlanta Health System
Disclosures: Holds stock in Entegrion, Inc.
Yasmine Khakoo, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Nothing to disclose.
Minesh P. Mehta, MD, Vice Chair, University of Maryland Medical School
Disclosures: Is a consultant with Karyopharm and serves as member of the Board of directors for Tocagen; Board of Directors: Oncoceutics; Received Oncoceutics 0.1% stock-option investment as a member of the Board of Directors.
Tom Mikkelsen, MD, Ontario Brain Institute
Disclosures: Hosted Society for Neuro-Oncology (SNO) dinner satellite symposium: “Tyrosine Kinase Inhibitors in Glioblastoma: Refining Precision Medicine” on Friday, November 22, 2019 sponsored by Clinical Care Options, LLC.
Douglas E. Ney, MD, University of Colorado School of Medicine
Disclosures: Receives compensation to serve on DNAtrix Therapeutics - Data Safety Monitoring Board. Receives research support from Orbus Therapeutics for role as Principal Investigator of national multi-site clinical trial and from Genentech for role as Principal Investigator of national multi-site clinical trial.
Nina Paleologos, MD, Advocate Good Samaritan Hospital
Disclosures: Nothing to disclose.
Roy E. Strowd, III, MD, MEd, Wake Forest School of Medicine
Disclosures: Has commercial relationships with Monteris Medical, Novocure Inc, and Lecturio. Receives research support from American Society of Clinical Oncology, JAZZ Pharmaceuticals, and Southeastern Brain Tumor Foundation.